Repligen Corporation logo

Repligen Corporation

RGEN | NASDAQ
Chart Builder DCF Calculator
$174.70
-$2.24 (-1.27%)
Nov 2, 2026, 9:47 AM ET · Market open

Company Profile

Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.

Key Executives

Name Position
Olivier Loeillot President, Chief Executive Officer & Director
Heather Ems Chief Information Officer
James R. Bylund Chief Operating Officer
Jason K. Garland Chief Financial Officer & Chief Compliance Officer
Anthony J. Hunt Advisor
Brian Douglass Senior VP & Chief Product Officer
George Scott Jr. Senior VP & General Counsel
Jacob K. Johnson Vice President of Investor Relations
Neil Whitfield Senior Vice President of Sales
Ralf Kuriyel Senior Vice President of Research & Development
Violetta Hughes Chief Accounting Officer

Latest SEC Filings

Date Type Title
Sep 30, 2026 425 Filing
Sep 28, 2026 4 Filing
Sep 25, 2026 4 Filing
Sep 22, 2026 4 Filing
Sep 15, 2026 8-K Current Report
Sep 08, 2026 425 Filing
Sep 08, 2026 8-K Current Report
Sep 08, 2026 4 Filing
Sep 04, 2026 EFFECT Filing
Sep 04, 2026 424B3 Filing
View All SEC Filings ➞
Repligen Corporation
Repligen Corporation logo
Country United States
IPO Date Apr 29, 1986
Industry Medical - Instruments & Supplies
Sector Healthcare
Employees 2,000
CEO Olivier Loeillot

Contact Details

Building 1 Waltham, Massachusetts 02453 United States

Stock Details

Ticker Symbol RGEN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000730272
CUSIP Number 759916109
ISIN Number US7599161095
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.